Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY
Autore:
KILBY JM; HOPKINS S; VENETTA TM; DIMASSIMO B; CLOUD GA; LEE JY; ALLDREDGE L; HUNTER E; LAMBERT D; BOLOGNESI D; MATHEWS T; JOHNSON MR; NOWAK MA; SHAW GM; SAAG MS;
Indirizzi:
UNIV ALABAMA,DEPT MED,908 20TH ST S BIRMINGHAM AL 35294 TRIMERIS INC DURHAM NC 27707 UNIV ALABAMA,DEPT MICROBIOL BIRMINGHAM AL 35294 DUKE UNIV,MED CTR,DEPT SURG ONCOL DURHAM NC 27710 PRINCETON UNIV,INST ADV STUDY PRINCETON NJ 08540 UNIV ALABAMA,HOWARD HUGHES MED INST BIRMINGHAM AL 35294
Titolo Testata:
Nature medicine
fascicolo: 11, volume: 4, anno: 1998,
pagine: 1302 - 1307
SICI:
1078-8956(1998)4:11<1302:PSOHRI>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; DYNAMICS IN-VIVO; DEXTRAN SULFATE; LEUCINE-ZIPPER; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; PROTEASE INHIBITORS; COMBINATION THERAPY; SYNTHETIC PEPTIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
48
Recensione:
Indirizzi per estratti:
Citazione:
J.M. Kilby et al., "POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY", Nature medicine, 4(11), 1998, pp. 1302-1307

Abstract

T-20, a synthetic peptide corresponding to a region of the transmembrane subunit of the HIV 1 envelope protein, blocks cell fusion and viral entry at concentrations of less than 2 ng/ml in vitro. We administered intravenous T-20 (monotherapy) for 14 days to sixteen HIV-infected adults in four dose groups (3, 10, 30 and 100 mg twice daily). There were significant, dose-related declines in plasma HIV RNA in all subjects who received higher dose levels. All four subjects receiving 100 mgtwice daily had a decline in plasma HIV RNA to less than 500 copies/ml, by bDNA assay. A sensitive RT-PCR assay (detection threshold 40 copies/ml) demonstrated that, although undetectable levels were not achieved in the 14-day dosing period, there was a 1.96 log(10) median decline in plasma HIV RNA in these subjects. This study provides proof-of-concept that viral entry can be successfully blocked in vivo. Short-term administration of T-20 seems safe and provides potent inhibition of HIV replication comparable to anti-retroviral regimens approved at present.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 16:17:30